201-14141





Lisa Medley/DC/USEPA/US

12/29/2005 09:42 AM

TO NCIC HPV@EPA

2006 JAN - 01 AM 8: 29

cc bcc

Subject Fw: Test Plan and Robust Study Summaries

Lisa Medley
OPPT/OSWER Docket - EPA HQ Docket Center
(Operated by ASRC Management Services)
1301 Constitution Ave NW Room B146 West
Washington DC 20460
202-566-0271 \*fax 202-566-0282

---- Forwarded by Lisa Medley/DC/USEPA/US on 12/29/2005 09:42 AM -----



Sandi MURPHY <sandi.murphy@arkemagro up.com>

TO NCIC OPPT@EPA, Rtk Chem@EPA

CC

12/23/2005 01:13 PM

Subject Test Plan and Robust Study Summaries

Attached please find the test plan and currently available robust study summaries for Tetradecyloxirane, (CAS# 7320-37-8, also called 1,2-epoxyhexadecane) which Arkema Inc volunteered to sponsor in the HPV program in a letter dated October 21, 2005. The test plan and robust study summaries will be updated as additional information becomes available.

If you have any questions please feel free to contact me. My contact information is listed below.

Thank you,

Sandi

Sandra Reiss Murphy, PhD
Toxicology Manager
Arkema Inc.
2000 Market Street
Philadelphia, PA 19103-3222
USA
+1.215.419.5881 (phone)
+1.215.419.5800 (fax)
sandi.murphy@arkemagroup.com





Test Plan 1-2-epoxyhexadecane.pdf Robust summaries tetradecyloxirane.pdf

201-16141A

OPPT COIC

# Test Plan for: Tetradecyloxirane [CASRN 7320-27-8]

Prepared for

U.S. Environmental Protection Agency HPV Challenge Program 1200 Pennsylvania Avenue Washington, DC 20460

Prepared by

Arkema Inc. 2000 Market Street Philadelphia, PA 19103-3222

#### 1 EXECUTIVE SUMMARY

IN 2005 Arkema Inc. volunteered to sponsor tetradecyloxirane (CAS#7320-38-7) also know as 1,2-epoxyhexadecane, in the US EPA High Production Volume (HPV) Challenge Program. This material was previously considered an orphan under the HPV program.

This report and test plan covers the physical property; environmental fate processes; and the ecological, mammalian, and genetic toxicity endpoints for tetradecyloxirane as appropriate for a chemical intermediate with controlled transport.

#### **Existing Data**

Data on physical properties, environmental fate, ecotoxicity, and mammalian and genetic toxicity were collected from available reports, published literature, and various standard compilations of physical property data. The collected data were reviewed for acceptability and entered into an International Uniform Chemical Information Database (IUCLID) dossier.

Ecotoxicity, mammalian toxicity, and genetic toxicity data were scored using the Klimisch et al. (1977) scoring system to assess data reliability. Data with scores of 1 or 2 were considered reliable and sufficient to assess an endpoint without supplementary data. Studies rated 4 were considered supplementary. Robust summaries were prepared for available reliable studies and relevant supplementary data and were entered into the IUCLID dossier.

Tetradecyloxirane is a metabolite of 1-hexadecene, which has been evaluated in the HPV Challenge Program as part of the as part of the higher olefins category. Some supplementary data for tetradecyloxicrane includes the assessment of 1-hexadecene.

Tetradecyloxirane is an isolated intermediate with controlled transport to a limited number second parties that use the chemical in a controlled way as an intermediate with a well-known technology. Repeat dose data up to 2 year studies in two species are available.

The proposed test plan is summarized in Table 1.

**Table 1. Proposed Tests for Tetradecyloxirane** 

Endpoint	Testing Proposed	Rationale
Melting point	No	Adequate existing information
Boiling point	No	Adequate existing information
Density	No	Adequate existing information
Partition coefficient	No	Adequate existing information
Water solubility	No	Estimated using EPIWIN v3.12
Photodegradation	No	Estimated using EPIWIN v3.12
Transport between environmental compartments	No	Estimated using EPIWIN v3.12
Stability in water	Yes	
Biodegradation	No	Adequate existing information
Acute fish	No	Adequate existing information
Acute Daphnia	No	Adequate existing information
Toxicity to algae	Yes	
Acute toxicity	No	Adequate existing information
Repeated dose toxicity	No	Adequate existing information
Reproductive toxicity	No	Adequate existing information
Developmental toxicity	No	Adequate existing information
Genetic toxicity	No	Adequate existing information

#### 1.1 TEST SUBSTANCE

#### 1.2 GENERAL SUBSTANCE INFORMATION

This material is used as a chemical intermediate with controlled transport. It is produced at a single location and shipped to a small number of second party users/locations where it is converted during processing to produce lubricants, surfactants, and additives for functional fluids for machinery, vehicles, and equipment. Any exposure potential would be limited to an industrial occupational setting. Tetradecyloxirane is an irritating material and a sensitizer.

Precautions are taken in manufacturing and processing to prevent contact. It is consumed and converted during processing. The products produced from the tetradecyloxirane are further diluted and used in formulations. There is no to very low potential for exposure to the tetradecyloxirane outside industrial occupational settings.

Table 2. General Substance Information

Compound	CAS No.	Molecular Formula	Molecular Weight (g/mol)	Estimated Purity of Named Substance	Structural Diagram
Tetradecyloxirane	7320-37-8	C <sub>16</sub> H <sub>32</sub> O	240.42	98%	MolWt: 240.43 C16\H32 O1 007320-37-8 Oxirane;≇etradecyl-

#### 1.3 REACTIVITY

Epoxides contain 3 membered carbon-carbon-oxygen rings which are reactive, due to the strain on the ring. Nucleophilic attack breaks a carbon-oxygen bond, opening the ring and relieving the strain. Generally, the result is the formation of a substituted alcohol; if the nucleophile is water, then diols or glycols are formed. Weak nucleophiles such as water require acid catalysts for the reaction to occur. Under acidic conditions, the nucleophile preferentially attacks the more substituted carbon in the ring, resulting in the formation of the less substituted alcohol. Under basic conditions, the nucleophile attacks the least hindered carbon in the ring and results in the formation of the more substituted alcohol. In living systems the enzyme epoxide hydrolase converts epoxides to trans-dihydrodiols. Based on these properties, this high molecular weight epoxide is stable under normal storage and handling conditions. Contact with acids, bases, or oxidizers can result in a low energy release.

#### 1.4 DISCUSSION OF THE ADEQUACY OF THE EXISTING DATA

Arkema has reviewed the existing data set and feels that the existing data are adequate to characterize several of the aquatic and health effects of tetradecyloxirane for the purposes of the EPA HPV Challenge Program. Table 1 indicates where additional data are proposed to be developed.

#### 2 PHYSICAL PROPERTY DATA

For tetradecyloxirane, data on physical properties were collected from reports, published literature, and various standard compilations of physical property data. The collected data were

reviewed for acceptability and entered into an International Uniform Chemical Information Database (IUCLID) dossier. Existing physical property data are summarized in Table 3 below.

Table 3. Physical Property Data for Tetradecyloxirane

Endpoint	Value	Source(s)
Melting Point	21°C <sup>(1)</sup>	The Dictionary of Substances and Their Effects (DOSE, 3rd Electronic Edition) 2005
Boiling Point	270 - 275 °C	Safety and Toxicity Data prepared for 1,2-epoxyhexadecane by Tracor Jitco July 26, 1978.
Density (g/cm <sup>3</sup> )	0.85 @ 20 °C	The Dictionary of Substances and Their Effects (DOSE, 3rd Electronic Edition) 2005
Vapor Pressure	ca. 0.00285 hPa @ 25 °C	EPISuite v3.12 (MPBPWIN V. 1.41)
Partition Coefficient (log Pow)	ca. 6.76 @ 25 °C	EPISuite v3.12 (KOWWIN v1.67)
Water solubility	0.045 mg/L @ 25 °C	EPISuite v3.12 (WSKOW v1.41)
	0.0006 mg/L	Wood, 1982

Existing physical property data are considered adequate; therefore, no additional testing is proposed.

#### 3 ENVIRONMENTAL FATE DATA

#### 3.1 PHOTODEGRADATION

The Atmospheric Oxidation Program for Microsoft Windows (EPISuite v 3.12, AOPWIN v1.91) was used to estimate the rate constant for the atmospheric, gas-phase reaction between photochemically produced hydroxyl radicals and organic chemicals. These rate constants were used to calculate atmospheric half-lives based upon average atmospheric concentrations of hydroxyl radicals and ozone. The results are presented below and indicate that there is a moderate reaction rate and it will not be persistent in air.

Hvdroxvl Radicals Reaction:

OVERALL OH Rate Constant = 18.7709 E-12 cm3/molecule-sec

Half-Life = 0.570 Days (12-hr day; 1.5E6 OH/cm3)

Half-Life = 6.838 Hrs

#### 3.2 ENVIRONMENTAL TRANSPORT AND DISTRIBUTION (FUGACITY)

Fugacity modeling was performed using EPISuite v3.12. The results are listed below:

Level III Fugacity Model:

	Mass Amount	Half-Life	Emissions
	(percent)	(hr)	(kg/hr)
Air	0.531	13.7	1000
Water	4.42	360	1000

 Soil
 31.2
 720
 1000

 Sediment
 63.8
 3.24e+003
 0

Persistence Time: 1.11e+003 hr

Based on this model the material is expected to partition primarily to soil and sediment.

#### 3.3 BIODEGRADATION

Aerobic degradation was 26% after 20 days, so the material is inherently biodegradable. No testing is proposed. (Waggy, G.T., 1992).

#### 3.4 STABILITY IN WATER (HYDROLYSIS)

There are no rate data related to the stability in water. Epoxides have the potential to undergo hydrolysis. Experience has shown that tetradecyloxirane is stable in water at neutral pH and room temperature, but will hydrolyze to form the glycol in acid solutions. Hydrolysis testing is proposed.

#### 4 ECOTOXICITY DATA

Ecotoxicity data were collected from reports and published literature. The collected data were reviewed for acceptability and entered into an International Uniform Chemical Information Database (IUCLID) dossier.

#### 4.1 ACUTE TOXICITY TO FISH

Data in the literature indicates that the LC50 is greater than the limit of solubility. (Deneer et al., 1988) Modeling makes the same prediction. No further testing is proposed.

#### 4.2 ACUTE TOXICITY, AQUATIC INVERTEBRATES (DAPHNIA)

The EC50 for Daphnia magna is reported to be 1.25 mg/l. These data are adequate. No further testing is proposed. (Waggy, GT, 1992)

#### 4.3 TOXICITY TO AQUATIC PLANTS (E.G., ALGAE)

No data on the toxicity to algae are available. Testing for algal toxicity is proposed.

#### 5 MAMMALIAN TOXICITY

Based on animal studies, tetradecyloxirane had low acute oral and dermal toxicity, was slightly irritating to eyes, severely irritating to skin, and caused skin sensitization. It was not mutagenic when tested in bacteria, but elicited chromosomal effects to some types of cells in culture, and was negative in others. Histopathological findings in subchronic dermal studies (13 week duration) were identified in the skin but not in tissues remote from the site of application. Long term dermal exposure resulted in the development of skin tumors in mice but not rats.

#### 5.1 ACUTE TOXICITY

The rat oral LD50 is greater than 5000 mg/kg. The rat dermal LD50 is greater than 2000 mg/kg. Clinical signs were noted in both studies during the observation period but no significant findings were noted at gross necropsy. (Springborn, 1996, 1996a) No further testing is proposed.

#### 5.2 IRRITATION AND SENSITIZATION

Results of animal studies showed moderate (Myers and Christopher, 1992) to severe skin irritation (Springborn, 1996b). Some signs of irritation persisted up to the observation recorded on day 10 after dosing. All animals had recovered by the study termination at day 14. Minor transient conjunctival irritation was noted after application of 0.1 ml to rabbit eyes. All animals recovered completely by day 7. (Myers and Christopher, 1992; Springborn, 1996c)

Tetradecyloxirane was tested to assess the dermal sensitization potential (delayed contact hypersensitivity) in Hartley-derived albino guinea pigs when administered by multiple topical applications. Based on the results of this study, this material is considered to be a contact sensitizer in guinea pigs. (Springborn, 1996d)

#### 5.3 REPEATED DOSE TOXICITY

Although the final reports of the NTP studies have never been published, the data are available in the archive. The information below was extracted from the records in the archive. (NTP Unpublished Study C55538)

#### Subchronic studies:

NTP conducted a 13 week skin painting study in rats as a dose range finding study prior to conducting a chronic study. Ten animals per sex per dose were administered test material 5 days per week for 13 weeks. The applied doses were 0, 62.5,125, 250, 500, and 1000 mg/kg at concentrations of 0, 3.75, 7.5, 15. 30, 60% in acetone.

Clinical observations were limited to irritation at the lower doses. At 500 mg/kg, during weeks 3 - 8, exfoliation of stratum corneum and alopecia were reported. Some females were thin. At 1000 mg/kg, during weeks 1 - 3, rough coats and slight erythema were observed; during weeks 4 - 13, exfoliation of the stratum corneum was also reported. During weeks 5 - 13, dark urine, emaciation (primarily in females), alopecia, and sores in treated area were reported.

There were compound related lesions observed in this study. These lesions the skin (site of application) and were manifested in a variety of changes. These changes consisted of

hyperkeratosis, parakeratosis, acanthosis, necrosis of cells, and necrosis with varying degrees of inflammation. In more severe cases, mostly high dose and mid dose animals, there was ulceration of the skin accompanied with acute and chronic inflammation. In one case, high dose male, there were pyogenic granulomas deep in the dermis and muscle.

Microscopic findings were limited to the skin and site of application. Deep dermal abscesses, focal ulceration, inflammation were reported.

A similar skin painting study was conducted in mice. Applied doses were 0, 62.5, 125, 250, 500, and 1000 mg/kg using test concentrations of 0, 0.9, 1.875, 3.75, 7.5, and 15%.

Reduced body weights were observed in males at doses > 250 mg/kg, beginning in the fourth week, but the body weights recovered to near controls for all doses by end of the study. Mean body weights of females varied too widely for any meaningful relationship to treatment.

Clinical observations, males: Males in all dose groups had sores on their backs likely due to fighting. Dose related signs of skin irritation were also noted. At 250 mg/kg, during week 7 some males had thin appearance. At 500 mg/kg, during week 7 survivors appear thin. During weeks 7 -13, conditions of survivors improved. At 1000 mg/kg, during week 11, three males had sores on their dorsal area.

Clinical observations, females: Dose related signs of skin irritation were noted. At 250 mg/kg: During weeks 8-9, rough coats and thin appearance were reported. Conditions improved through the remainder of the study. At 500 mg/kg, in week 7, survivors appeared thin. Condition improved for the remainder of the study. At 1000 mg/kg from week 7, thin appearance and dermal effects were reported until the end of the study.

Mortality: 2m/3f @ 250; 4m/4f @ 500; 8m/4f @ 1000 mg/kg; most deaths occurred during weeks 6 - 8.

Microscopic findings: hyperkeratosis (minimal to moderate) in 14 mice, parakeratosis in 3 mice, and epithelial hyperplasia in 8 mice. Except for the tissue changes in the skin of treated mice, there were no tissue changes attributable to the effects of the test material in any of the treated mice examined.

Chronic Toxicity/Carcinogenicity:

NTP conducted a 2 year skin painting study in rats . Fifty animals per sex per dose were administered test material 5 days per week for 103 weeks. The applied doses were 0, 62.5 and 125 mg/kg in acetone with concentrations of 0, 3.75, 7.5% (adjusted based on body weight to allow for administration of 600 microliters).

The test material was a skin irritant and induced proliferative changes when applied topically. No consistent compound related reduction in body weight occurred in any of the treatment groups. Periodic weight fluctuations were attributed to problems with the automatic watering system. The Pathology Working Group which evaluated the study results concluded that 2-epoxyhexadecane in a two-year skin paint study did not produce any compound related neoplastic or systemic toxic lesions in F344 rats.

NTP conducted a similar 2 year skin painting study in mice. Fifty animals per sex per dose were administered test material 5 days per week for 103 weeks. The applied doses were 0, 62.5 and 125 mg/kg in acetone with concentrations adjusted based on body weight to allow for administration of 200 microliters.

All groups of male mice, including controls, had a high incidence of subcutaneous, mesenchymal neoplasms including malignant sarcoma, fibrosarcoma, neurofibrosarcoma, benign fibroma, with a combined incidence of 5 (10%), 8 (16%) and 13 (26%) in the control, low, and high dose groups. Only one fibrosarcoma was clearly identified as occurring at the application site. The tumors were all visible grossly.

There was a modest increase in the incidence of hepatocellular adenomas in all groups of male mice. The incidence of hepatocellular carcinoma was low in control male mice and average for treated animals.

The pathology working group concluded that 1,2-epoxyhexadecane in a two year skin painting study was associated with a dose-related increase in subcutaneous mesenchymal neoplasms in male B6C3F1 mice. A clear relationship between the location of the neoplasms and the area of skin exposure to the test compound cannnot be established from the data except for one tumor.

There were no other neoplastic or systemic toxic compound related effects in B6C3F1 mice. The pathology working group considered the modest increase in hepatocellular tumors in male mice not to be of biological significance.

These data are adequate to assess the repeated dose toxicity of tetradecyloxirane. No further testing is proposed.

#### 5.4 REPRODUCTIVE AND DEVELOPMENTAL TOXICITY

For materials such as tetradecyloxirane, with limited exposure potential, the guidelines allow for reduced testing if there is adequate information from repeated dose studies for hazard assessment.

No information on the potential reproductive or developmental toxicity of tetradecyloxirane was located. However, there were no adverse histopathological findings in the reproductive tracts of rats or mice exposed dermally for 13 weeks or 2 years.

In addition to meeting the condition for reduced testing, there is supplementary information relevant to the material indicating that it would not be expected to affect reproductive performance or development of offspring.

The supplementary indications come from the available data for the higher olefins and their metabolism. Tetradecyloxirane is a metabolite of hexadecene. Hexadecene has been evaluated in the HPV program as part of the higher alpha olefins category of materials.

*In vivo*, hexadecene is metabolized to 1,2-dihydroxyhexadecane through a tetradecyloxirane intermediate. The conversion of tetradecyloxirane to 1,2-dihydroxyhexadecane is dependent upon epoxide hydrolase. Based on the information from the alpha-olefins category, no reproductive or developmental effects are anticipated. Since tetradecyloxirane is the reactive metabolite, the evaluation of hexadecene is relevant since the ultimate metabolite is the same for both compounds. The materials tested in the alpha-olefins category did not elicit reproductive or developmental effects at doses up to 1000 mg/kg in rats.

In addition, there is information on higher mmolecular weight analogies and materials with higher degrees of epoxidation, eg, epoxidized oils. As in the case of the alpha-olefins, they did

not elicit any reproductive or developmental effects in rats at doses up to 1000 mg/kg. Based on the lack of effects in structurally similar materials of lower and higher molecular weight, and, degree of epoxidation, there is adequate information upon which to base a screening level hazard assessment for these endpoints.

Because the material is an intermediate with limited transport and supplementary data are available regarding reproductive and developmental effects, no further testing is proposed.

#### 6 GENETIC TOXICITY

Data from various *in vitro* gene mutation and chromosomal aberration tests of tetradecyloxirane were obtained from company-sponsored studies or from the scientific literature. *In vitro* genetic toxicity data are summarized in Table 4.

Table 4. In Vitro Mutagenicity and Genotoxicity of Tin Tetrachloride

Endpoint	Results	Source
Bacterial reverse mutation assay (single strain and multiple strains)	Negative	Hengler, W.C., Slesinski, R.S. and Frank, F.R. (1984); Canter et al., 1986.
Mouse lymphoma assay	Positive	McGregor DB, et al., 1988.
Sister Chromatid Exchange Assay	Negative	von der Hude et al., 1991, Slesinski, et al., 1984
(Chinese hamster cells)		Union Carbide Corporation, 1984

There are adequate data to assess genotoxicity. No further testing is proposed.

#### 7 REFERENCES

Canter DA, et al. Comparative Mutagenicity of Aliphatic Epoxides in Salmonella. Mutat Res 172(2):105-138, 1986

Deneer JW Sinnige TL Seinen W Hermens JL A Quantitative Structure-Activity Relationship For The Acute Toxicity Of Some Epoxy Compounds To The Guppy. Aquat Toxicol., 13: 195-204, 1988

Dow Europe GMBH MSDS alpha-Olefin Epoxide C-16, 30/3/04 EPI Suite v3.12, US EPA

Hengler, W.C., Slesinski, R.S. and Frank, F.R. (1984). Alpha-Olefin Epoxide C-16 Salmonella/Microsome (Ames) bacterial mutagenicity assay.

McGregor DB, et al. Responses of the L5178Y TK+/TK- Mouse Lymphoma Cell Forward Mutation Assay: III. 72 Coded Chemicals. Environ Mol Mutagen 12(1):85-154, 1988.

Myers, R.C. and Christopher, S.M. (1992). .... cutaneous and ocular irritancy testing using the rabbit. US National Toxicology Program (NTP) Unpublished study (C55538) summarized by Tracor-Jitco, Inc., Subchronic Test Of 1,2-Epoxyhexdecane (C55538) In B6C3F1 Mice And Fisher 344 Rats By Dermal Application, EPA/OTS DOC 40-8077013 NTIS/OTS0508872

Nycum, J.S. (1968). Single dose toxicity and irritation studies on Epoxides

Safety and Toxicity Data prepared for 1,2-epoxyhexadecane by Tracor Jitco July 26, 1978.

Slesinski, R.S. and Frank, F.R. (1984). a-Olefin Epoxide -16 in vitro Genotoxicity Studies: Sister Chromatid Echange Test.

SPRINGBORN ENVIRONMENTAL SCIENCES Acute Oral Toxicity Study in Rats with Vikolox 16, SLI STUDY NO. 3255.80, 19 August 1996.

SPRINGBORN ENVIRONMENTAL SCIENCES Dermal Sensitization Study in Guinea Pigs with Vikolox 16, SLI STUDY NO. 255.84, 10 Sept 1996.

SPRINGBORN ENVIRONMENTAL SCIENCES, Primary Skin Irritation Study in Rabbits with Vikolox 16, SLI STUDY NO. 255.83 19 August 1996.

SPRINGBORN ENVIRONMENTAL SCIENCES. Acute dermal toxicity study in rats with Vikolox 16, SLI STUDY NO. 3255.81, 19 August 1996.

SPRINGBORN ENVIRONMENTAL SCIENCES. Primary Eye Irritation Study in Rabbits with Vikolox 16, SLI STUDY NO. 255.82, 19 August 1996.

The Dictionary of Substances and Their Effects (DOSE, 3rd Electronic Edition) 2005 by The Royal Society of Chemistry/Knovel Corp.

Union Carbide Corporation. Alpha-Olefin Epoxide C-16 Salmonella/Microsome (Ames) Bacterial Mutagenicity Assay With Cover Letter. TSCA 8(d) submission. TSCATS Microfiche No. 206602. 03/05/84.

von der Hude W, Carstensen S, Obe G, Structure-Activity Relationships Of Epoxides: Induction Of Sister-Chromatid Exchanges In Chinese Hamster V79 Cells, Mutat Res, 249: 55-70,1991.

Wood WP, Properties Of Alkyl-Epoxides - Table I With Cover Letter, US Environmental Protection Agency EPA/OTS DOC 40-8277016, NTIS/OTS0508875

2006 JAN - 07 AM 8: 29

201-16141B

# IUCLID

# **Data Set**

**Existing Chemical** 

CAS No.

**EINECS Name** 

EC No. Molecular Formula : ID: 7320-37-8

: 7320-37-8

: tetradecyloxirane

: 230-786-2

: C16H32O

Producer related part

Company Creation date : Arkema Inc. : 20.12.2005

Substance related part

Company Creation date

: Arkema Inc. : 20.12.2005

**Status** 

Memo

Printing date

: 23.12.2005

Revision date

Date of last update

: 23.12.2005

**Number of pages** 

: 43

Chapter (profile)

Reliability (profile)

: Chapter: 1, 2, 3, 4, 5, 6, 7, 8, 10 : Reliability: without reliability, 1, 2, 3, 4

Flags (profile)

Flags: without flag, confidential, non confidential, WGK (DE), TA-Luft (DE), Material Safety Dataset, Risk Assessment, Directive 67/548/EEC, SIDS

#### 1. General Information

**Id** 7320-37-8 Date 23.12.2005

#### 1.0.1 APPLICANT AND COMPANY INFORMATION

**Type** : cooperating company

Name : Arkema Inc. Contact person Date : Sandra Murphy : 20.12.2005 : 2000 Market Street Street

: PA 19103 Philadelphia Town Country

: United States : 215 419 5881 Phone Telefax : 215 419 5800

Telex Cedex

Email : sandi.murphy@arkemagroup.com

Homepage

Source : Arkema Inc. Philadelphia, PA USA

Flag : non confidential

22.12.2005

#### 1.0.2 LOCATION OF PRODUCTION SITE, IMPORTER OR FORMULATOR

#### 1.0.3 IDENTITY OF RECIPIENTS

#### 1.0.4 DETAILS ON CATEGORY/TEMPLATE

#### 1.1.0 SUBSTANCE IDENTIFICATION

**IUPAC Name** 

Smiles Code : O(C1CCCCCCCCCCCC)C1

Molecular formula : C16-H32-O Molecular weight : 240.42

Petrol class

Source : Arkema Inc. Philadelphia, PA USA

Attached document : EHD.bmp

(CH<sub>2</sub>)<sub>13</sub> -CH<sub>3</sub>

21.12.2005

#### 1. General Information

ld 7320-37-8 **Date** 23.12.2005

#### 1.1.1 GENERAL SUBSTANCE INFORMATION

Purity type : typical for marketed substance

Substance type : organic Physical status : liquid

Purity : ca. 98 % w/w
Colour : colorless
Odour : ether-like odour

Source : Arkema Inc. Philadelphia, PA USA

Reliability : Body weight data indicate a probable toxic effect at 10% and

above in males and 20% and above in females.

22.12.2005

#### 1.1.2 SPECTRA

Type of spectra : IR

**Attached document** : IR spectrum tetradecyloxirane.pdf

22.12.2005 (10)

#### 1.2 SYNONYMS AND TRADENAMES

#### 1,2-epoxyhexadecane

21.12.2005

Vikolox (R) 16

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005

#### 1.3 IMPURITIES

Purity : typical for marketed substance

CAS-No : 629-73-2 EC-No : 211-105-8 EINECS-Name : hexadec-1-ene

Molecular formula :

**Value** : ca. 2 % w/w

Source : Arkema Inc. Philadelphia, PA USA

21.12.2005

#### 1.4 ADDITIVES

#### 1.5 TOTAL QUANTITY

#### 1.6.1 LABELLING

Symbols : Xn, N, ,

#### 1. General Information

**Id** 7320-37-8 Date 23.12.2005

Nota

**R-Phrases** (38) Irritating to skin

(40) Possible risks of irreversible effects

(51) Toxic to aquatic organisms

(53) May cause long-term adverse effects in the aquatic environment

S-Phrases

21.12.2005 (3)

#### 1.6.2 CLASSIFICATION

#### 1.6.3 PACKAGING

#### 1.7 USE PATTERN

Type of use industrial

Category Chemical industry: used in synthesis

Remark Used primarily in the production of additives for functional fluids

Source Arkema Inc. Philadelphia, PA USA

21.12.2005

#### 1.7.1 DETAILED USE PATTERN

**Industry category** : 3 Chemical industry: chemicals used in synthesis

33 Intermediates Use category

Extra details on use category : Substance processed elsewhere No extra details necessary

**Emission scenario document** available

Product type/subgroup

**Tonnage for Application** Year

Fraction of tonnage for application

Fraction of chemical in formulation : Production : yes: Formulation

Processing

yes: III Multi-purpose equipment

Private use Recovery

: Arkema Inc. Philadelphia, PA USA Source

21.12.2005

#### 1.7.2 METHODS OF MANUFACTURE

Origin of substance Synthesis Production Type

Source : Arkema Inc. Philadelphia, PA USA

21.12.2005

# Date 23.12.2005 1.8 REGULATORY MEASURES 1.8.1 OCCUPATIONAL EXPOSURE LIMIT VALUES 1.8.2 ACCEPTABLE RESIDUES LEVELS 1.8.3 WATER POLLUTION 1.8.4 MAJOR ACCIDENT HAZARDS 1.8.5 AIR POLLUTION 1.8.6 LISTINGS E.G. CHEMICAL INVENTORIES 1.9.1 DEGRADATION/TRANSFORMATION PRODUCTS 1.9.2 COMPONENTS 1.10 SOURCE OF EXPOSURE 1.11 ADDITIONAL REMARKS 1.12 LAST LITERATURE SEARCH Type of search : Internal and External Chapters covered : 3, 4, 5 Date of search : 07.12.2005 21.12.2005 1.13 REVIEWS

1. General Information

**Id** 7320-37-8

#### 2. Physico-Chemical Data

ld 7320-37-8 **Date** 23.12.2005

#### 2.1 MELTING POINT

Value : 21 °C

Sublimation

Method

**Year** : 1999

GLP

Test substance

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

22.12.2005 (21)

#### 2.2 BOILING POINT

**Value** :  $= 270 - 275 \, ^{\circ}\text{C}$  at

Decomposition

Method : other: micro, capillary visual

Year : GLP : Test substance :

Remark : Literature values 104 - 106 C at 0.2 mm Hg

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

22.12.2005 (14)

#### 2.3 DENSITY

Type : density

**Value** : .846 at 20 °C

Source : ATOFINA Chemicals Inc. Philadelphia

**Reliability** : (2) valid with restrictions

22.12.2005 (21)

#### 2.3.1 GRANULOMETRY

#### 2.4 VAPOUR PRESSURE

**Value** : ca. .00285 hPa at 25 °C

Decomposition

**Method** : other (calculated)

Year

GLP : no Test substance : no data

Result : Boiling Pt, Welting Pt, Vapor Pressure Estimations (MPBPWIN v1.41):

VP(mm Hg,25 deg C): 0.00214 (Modified Grain method

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

22.12.2005 (7)

#### 2. Physico-Chemical Data

**Id** 7320-37-8 Date 23.12.2005

#### PARTITION COEFFICIENT

Partition coefficient octanol-water ca. 6.76 at 25 °C Log pow

pH value

Method other (calculated)

Year

**GLP** 

Test substance : as prescribed by 1.1 - 1.4

: KOWWIN Program (v1.67) Method

: WSKOW v1.41 Results -----Result

Log Kow (estimated): 6.76

Log Kow (experimental): not available from database Log Kow used by Water solubility estimates: 6.76

Equation Used to Make Water Sol estimate:

Log S (mol/L) = 0.796 - 0.854 log Kow - 0.00728 MW +

Correction

(used when Melting Point NOT available)

Correction(s): Value

No Applicable Correction Factors

Log Water Solubility (in moles/L): -6.724 Water Solubility at 25 deg C (mg/L): 0.045

Source Arkema Inc. Philadelphia, PA USA

Reliability (2) valid with restrictions

22.12.2005 (4)

#### 2.6.1 SOLUBILITY IN DIFFERENT MEDIA

Solubility in : Water

Value : ca. .045 mg/l at 25 °C

pH value

concentration at °C

Temperature effects

Examine different pol. :

at 25 °C pKa

Description Stable

Deg. product

Method other: estimate

Year

**GLP** 

Test substance

Source : Arkema Inc. Philadelphia, PA USA

Reliability : (2) valid with restrictions

22.12.2005 (4)

Solubility in Water

Value ca. .0006 mg/l at °C

pH value

at °C concentration

**Temperature effects** 

## 2. Physico-Chemical Data

ld 7320-37-8 **Date** 23.12.2005

Examine different pol.

pKa : at 25 °C

Description Stable

Deg. product

Method : other

Year :

Test substance

Method : Estimate based on structure

23.12.2005 (26)

#### 2.6.2 SURFACE TENSION

#### 2.7 FLASH POINT

Value : 93 °C

Туре

Method : other: closed cup

Year : GLP : Test substance :

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

22.12.2005 (21)

#### 2.8 AUTO FLAMMABILITY

#### 2.9 FLAMMABILITY

#### 2.10 EXPLOSIVE PROPERTIES

#### 2.11 OXIDIZING PROPERTIES

#### 2.12 DISSOCIATION CONSTANT

#### 2.13 VISCOSITY

#### 2.14 ADDITIONAL REMARKS

#### 3. Environmental Fate and Pathways

ld 7320-37-8 **Date** 23.12.2005

#### 3.1.1 PHOTODEGRADATION

#### 3.1.2 STABILITY IN WATER

#### 3.1.3 STABILITY IN SOIL

#### 3.2.1 MONITORING DATA

#### 3.2.2 FIELD STUDIES

#### 3.3.1 TRANSPORT BETWEEN ENVIRONMENTAL COMPARTMENTS

Type : fugacity model level III

Media

Air : % (Fugacity Model Level I)
Water : % (Fugacity Model Level I)
Soil : % (Fugacity Model Level I)
Biota : % (Fugacity Model Level II/III)
Soil : 31.2 % (Fugacity Model Level II/III)

Method : other: model

Year

**Result** : Level III Fugacity Model:

Mass Amount Half-Life Emissions

 (percent)
 (hr)
 (kg/hr)

 Air
 0.531
 13.7
 1000

 Water
 4.42
 360
 1000

 Soil
 31.2
 720
 1000

 Sediment
 63.8
 3.24e+003
 0

 Persistence Time:
 1.11e+003 hr

EPI SUMMARY (v3.12)

Source : Arkema Inc. Philadelphia, PA USA

21.12.2005

#### 3.3.2 DISTRIBUTION

#### 3.4 MODE OF DEGRADATION IN ACTUAL USE

#### 3.5 BIODEGRADATION

Type : aerobic

Inoculum

Contact time

**Degradation** : = 26 ( $\pm$ ) % after 20 day(s)

Result

#### 3. Environmental Fate and Pathways

ld 7320-37-8 **Date** 23.12.2005

Deg. product : Method : Year : GLP :

GLP : yes

Test substance :

**Remark**: Data provided by Dow.

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

22.12.2005 (24)

Type : aerobic

Inoculum

Deg. product

Method : other: Modeled estimate

Year :

Test substance

**Result** : Probability of Rapid Biodegradation (BIOWIN v4.01):

Linear Model : 0.3942
Non-Linear Model : 0.1201
Expert Survey Biodegradation Results:
Ultimate Survey Model: 2.9575 (weeks )
Primary Survey Model : 3.7602 (days )
Readily Biodegradable Probability (MITI Model):

Linear Model : 0.6733 Non-Linear Model : 0.766 : Arkema Inc. Philadelphia, PA USA

**Source** 22.12.2005

#### 3.6 BOD5, COD OR BOD5/COD RATIO

#### 3.7 BIOACCUMULATION

#### 3.8 ADDITIONAL REMARKS

Date 23.12.2005

#### 4.1 ACUTE/PROLONGED TOXICITY TO FISH

Type : semistatic

**Species**: Lebistes reticulatus (Fish, fresh water)

Exposure period : 14 day(s)
Unit : µmol/l

**Method**: Five concentrations geometrically increaseing with a factor of 1,8 were

tested for each material, exposing 10 fish to each concnetration. Actual concnetrations were measured at least four times after and four times before renewal . Concnetrations were deteremined using G-LC with an

FID detector.

Result : For 1,2-epoxyhexadecane no LC50 could be determined. It is likely that

the solubility of this compound is too low to cause lethal effects.

**Conclusion** : LC50 value is greater than the limit of water solubility.

**Reliability** : (2) valid with restrictions

23.12.2005 (2)

**Type** : other: model estimate

Species

Exposure period :

Unit : mg/l

LC50 : ca. .323 calculated

Method : other: ECOSAR V0.99

Year

GLP

Test substance

Result : ECOSAR v0.99h Class(es) Found

-----

**Epoxides** 

Predicted Values: Neutral Organic SAR: Fish,14-day LC50 0.023 mg/l\*

(Baseline Toxicity)

Epoxides: Fish, 96-hr LC50 0.323 mg/l \* Epoxides: Fish, 14-day LC50 0.351 mg/l \*

Note: \* = asterisk designates: Chemical may not be soluble

enough to measure this predicted effect. Fish and daphnid acute toxicity log Kow cutoff: 5.0

MW cutoff: 1000

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (4)

#### 4.2 ACUTE TOXICITY TO AQUATIC INVERTEBRATES

Type : static

Species : Daphnia magna (Crustacea)

Exposure period

Unit : mg/l

**EC50** : = 1.25 measured/nominal

Method

Year :

GLP : yes

Test substance :

#### 4. Ecotoxicity

ld 7320-37-8 **Date** 23.12.2005

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

22.12.2005 (3) (24)

Type : other: modeled estimate
Species : Daphnia sp. (Crustacea)

Exposure period : 48 hour(s)
Unit : mg/l

EC50 : ca. .038 calculated

Result : ECOSAR v0.99g Class(es) Found: Epoxides

Predicted Daphnid 48-hr LC50 0.038 mg/L (ppm) \*

Note: \* = asterisk designates: Chemical may not be soluble

enough to measure this predicted effect. Fish and daphnid acute toxicity log Kow cutoff: 5.0

MW cutoff: 1000

Source : Arkema Inc. Philadelphia, PA USA

28.05.2004

#### 4.3 TOXICITY TO AQUATIC PLANTS E.G. ALGAE

#### 4.4 TOXICITY TO MICROORGANISMS E.G. BACTERIA

Type : aquatic

Species

Exposure period

Unit : mg/l

**EC10** : measured/nominal

**EC50** : = 5000

Method

Year

GLP : yes

Test substance :

Source : Arkema Inc. Philadelphia, PA USA

Data provided by Dow

**Reliability** : (2) valid with restrictions

22.12.2005 (3) (24)

#### 4.5.1 CHRONIC TOXICITY TO FISH

#### 4.5.2 CHRONIC TOXICITY TO AQUATIC INVERTEBRATES

#### 4.6.1 TOXICITY TO SEDIMENT DWELLING ORGANISMS

#### 4.6.2 TOXICITY TO TERRESTRIAL PLANTS

#### 4.6.3 TOXICITY TO SOIL DWELLING ORGANISMS

4. Ecotoxicity	ld 7320-37-8 <b>Date</b> 23.12.2005
4.6.4 TOX. TO OTHER NON MAMM. TERR. SPECIES	
4.7 BIOLOGICAL EFFECTS MONITORING	
4.8 BIOTRANSFORMATION AND KINETICS	
4.9 ADDITIONAL REMARKS	
13 / 43	

#### 5.0 TOXICOKINETICS, METABOLISM AND DISTRIBUTION

In Vitro/in vivo : In vitro

Type : Metabolism

**Species**: other: mammalian liver

Number of animals

Males

Females

**Doses** 

Males : Females :

Vehicle Method

Year : 1975
GLP : no
Test substance : other TS

**Method**: 1-Hexadecene dissolved in acetone and suspended in 0.1

M phosphate buffer, pH 7.4, was incubated with rabbit liver microsomes in the presence of an NADPH-generating system. The reaction was terminated by the addition of sodium hydroxide, and the mixture extracted with ether containing 1,2-epoxytetradecane or 1,2-dihydroxytetradecane as the in-

ternal reference for the quantitative determination of metabolites. The ethereal extract was subjected to

preparative silica gel thin-layer chromatography developed in benzene-acetone (5:1). Authentic ,2-dihydroxytetradecane and 1,2-dihydroxyhexadecane or 1,2-epoxytetradecane and 1,2-epoxyhexadecane co-chromatographed as single bands at Rf 0.2 or 0.7, respectively. Each zone of the chromatogram was eluted with ethanol. The eluate from the Rf 0.2 zone was trimethylsilylated after the evaporation of the solvent and analyzed by gas-chromatography mass spectroscopy. Gas-chromatographic data (retention time: 7.4 min on a 2% OV-17 column at 210 C)and the mass spectrum were identical with those of authentic 1,2-dihydroxyhexadecane di-trimethylsilyl ether; a molecular ion peak with m/e 402 appeared together with fragment ion peaks characteristic of the glycol-TMS derivative at m/e 103 (strong intensity,

TMS O CH2 +) and 299 (strong intensity,

TMS--O- CH+--(CH2)13CH3). The eluate from Rf 0.7 zone was concentrated and directly analyzed by gas-chromatography-mass spectroscopy. Gas-chromatographic data (retention time: 4.5 min under the above conditions) and the mass spectrum obtained were identical with those of authentic 1,2-epoxyhexadecane; a molecular ion peak with role 240 appeared together with fragment ion peaks

with m/e 57 (strong intensity) and 43.

**Result** : The formation of the epoxide was observed only when the

olefin was incubated in the presence of the epoxide hydrolase inhibitor 1,2-epoxydecane (10 mM). These results indicate that 1-hexadecene is metabolized to 1,2-dihydroxyhexadecane via 1,2-epoxyhexadecane.

Enzymatic conversion of the epoxide to the glycol by rabbit

liver microsomes has previously been reported.

Source : ATOFINA Chemicals Inc. Philadelphia

**Test substance** : 1-Hexadecene

**Conclusion** : This study corroborates the enzymatic conversion of the

epoxide to the glycol by rabbit liver microsomes as

previously reported.

**Reliability** : (1) valid without restriction

08.12.2005 (25)

#### 5.1.1 ACUTE ORAL TOXICITY

Type : LD50

**Value** : > 5000 mg/kg bw

Species : rat

Strain: Sprague-DawleySex: male/female

Number of animals : 1

Vehicle

**Doses** : 5000 mg/kg bw

Method

Year

GLP : yes Test substance :

**Method** : The single-dose oral toxicity was evaluated in

Sprague-Dawley rats. A limit test was performed in which one group of five male and five female rats received a single oral administration of the test article at a dose of 5000 mg/kg body weight. Following dosing, the limit test rats were observed daily and weighed weekly. A gross necropsy examination was performed on all limit test animals at the

time of scheduled euthanasia (day 14).

Year study performed: 1996

**Result**: No mortality occurred during the limit test. The most

notable clinical abnormalities observed during the study included fecal/urine stain, rough haircoat, dark material around nose, scabs/reddened skin/hairloss and/or swelling on various areas, decreased defecation and soft stools. Body weight gain was noted for all animals during the test

period. No significant gross internal findings were observed

at necropsy on study day 14.

Arkema Inc. Philadelphia, PA USA

**Test condition**: Yound adult rats were used.

Test substance : Vikolox (R) 16

**Conclusion**: Under the conditions of this test, the acute oral LD50 was

estimated to be greater than 5000 mg/kg in the rat.

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

22.12.2005 (16)

#### 5.1.2 ACUTE INHALATION TOXICITY

#### 5.1.3 ACUTE DERMAL TOXICITY

Source

Type : LD50

**Value** : > 2000 mg/kg bw

Species : rat

Strain : Sprague-Dawley
Sex : male/female

Number of animals : 10

Vehicle

**Doses** : 2000 mg/kg

Method

Year :

GLP : yes Test substance :

**Method** : The single-dose dermal toxicity was evaluated on

Sprague-Dawley rats. A limit test was performed in which one group of five male and five female rats received a single dermal administration of the test article. The test article was administered as received from the Sponsor. April 8, 1996

(GLP initiation date)

Result : No mortality occurred during the limit test. Clinical

abnormalities observed during the study included urine stain and dark material around the facial area. Dermal irritation was noted at the site of test article application. Body weight loss was noted in four females during the day 0 to 7 body weight interval. One female did not regain her original body weight by study day 14. Body weight gain was noted for all other animals during the test period. No significant gross internal findings were observed at necropsy on study

day 14.

Source : Arkema Inc. Philadelphia, PA USA

**Test condition** : On day -1, the fur was removed from the dorsal trunk area (~ 10% of the animal's body surface area) of the animals

chosen for the limit test using an animal clipper. Young adult, Sprague-Dawley Crl:CD®BR VAF/Plus® rats received a dose of 2000 mg/kg body weight. The density of the test article was determined to be 0.85 g/mL. On the following day

(day 0), the test article was administered dermally to approximately 10% of the body surface area (BSA). The test article was spread evenly over the test area and held in contact with the skin with an appropriately sized 4 ply porous gauze dressing backed with a plastic wrap which was placed over the gauze dressing (occlusive binding). Removal and ingestion of the test article was prevented by placing an elastic wrap over the trunk and test area. The elastic wrap was further secured with a tape harness on the cranial end of the trunk and then secured with adhesive tape around

the trunk at the caudal end.

After an approximate 24-hour exposure period, the gauze dressing, plastic and elastic wrap were removed and the comers of the test site delineated using a marker. Residual test article was removed using gauze moistened with distilled water followed by dry gauze.

Following dosing, the limit test rats were observed daily and weighed weekly. A gross necropsy examination was performed on all limit test animals at the time of scheduled

euthanasia (day 14).

Test substance : Vikolox 16

Conclusion : Under the conditions of this test, the acute dermal LD50 of

Vikolox 16 was estimated to be greater than 2000 mg/kg in

(19)

the rat.

**Reliability** : (1) valid without restriction

Type : LD50

Value : = 10 ml/kg bw

Species

22.12.2005

Strain :
Sex :
Number of animals :
Vehicle :
Doses :

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

22.12.2005 (13)

#### 5.1.4 ACUTE TOXICITY, OTHER ROUTES

Type : LD50

Value : = 4.92 ml/kg bw

Species : rat Strain :

Sex

Number of animals : Vehicle : Doses :

Route of admin. : i.p.

Exposure time :

Source : Arkema Inc. Philadelphia, PA USA

Data provided by Dow Chemical Company

Reliability : (2) valid with restrictions

22.12.2005

#### 5.2.1 SKIN IRRITATION

Species: rabbitConcentration: undilutedExposure: SemiocclusiveExposure time: 4 hour(s)

Number of animals : 6 Vehicle : 5

Result : highly irritating
Classification : irritating

Method

Year

GLP : yes Test substance :

**Method** : The potential irritant and/or corrosive effects were

evaluated on the skin of New Zealand White rabbits. April

8, 1996 (GLP initiation date)

**Result** : Exposure to the test article produced slight edema and

blanching greater than 50% of the test site on 6/6 test sites at the 1 hour scoring interval. The dermal irritation resolved completely in all animals by study day 14. An additional dermal finding included desquamation, which was noted in all animals during the study but which resolved

between days 9 and 14 in all cases.

Average scores
TIME ERY EDEMA
1 Hour 4 2
24 Hours 3.7 2

48 Hours 3.3 1.2 72 Hours 3.3 1 7 Days 1.2 0 9 Days 0.8 0 10 Days 1 0 14 Days 0 0

Source : Arkema Inc. Philadelphia, PA USA

**Test condition** : Each of six adult, New Zealand White rabbits received a 0.5

mL dose of the test article as a single dermal application. The test article was administered as received from the Sponsor. The test article was placed in a beaker, heated and maintained in a water bath at 37°C. Test article was heated

to liquefy but was not diluted to a concentration.

On day -1, the fur was removed from the dorsal area of the

trunk using an animal clipper.

On the following day (day 0), the test article was applied

to a small area of intact skin on each test animal

(approximately 1 inch x 1 inch)

The test article was administered under the gauze patch covered by an elastic wrap over the trunk and test area (semi-occlusive binding). The elastic wrap was then further secured with adhesive tape around the trunk at the cranial and caudal ends.

After a four-hour exposure period, the elastic wrap and gauze patch were removed. Residual test article was removed using gauze moistened with distilled water followed by dry gauze.

Test sites were subsequently examined and scored for dermal irritation for up to 14 days following patch removal.

Animals were examined for signs of erythema and edema and the responses scored at approximately 1, 24, 48 and 72 hours and up to 14 days after patch removal according to the Macroscopic Dermal Grading System which is based on Draize.

Test substance : Vikolox (R) 16

**Conclusion**: Under the conditions of this test, the material is

considered to be an irritant to the skin of the rabbit.

**Reliability** : (1) valid without restriction

22.12.2005 (18)

Species : rabbit

Concentration

Exposure
Exposure time

Number of animals

Vehicle : PDII : 3.

Result : moderately irritating

Classification

Method : Year : GLP :

Test substance

Result : moderate (Draize score - 3.8)
Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (8)

Species :
Concentration :
Exposure :
Exposure time :

Number of animals : Vehicle : PDII :

**Result**: moderately irritating

Classification : irritating

Method :
Year :
GLP :
Test substance :

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (13)

#### 5.2.2 EYE IRRITATION

Species : rabbit
Concentration : undiluted
Dose : .1 ml

Exposure time : Comment : Number of animals : 6 Vehicle : Result :

Classification : irritating

Method

Year :

GLP : yes

**Test substance** : as prescribed by 1.1 - 1.4

**Method** : The potential irritant and/or corrosive effects were

evaluated on the eyes of New Zealand White rabbits. April 8, 1996 (GLP

initiation date)

**Result** : ocular irritation score = [corneal opacity x area x 5] +

[iritis x 5] + [(conjunctival redness + swelling +

discharge) x 2]

The group mean irritation score was then calculated for each scoring interval based on the number of animals initially dosed in each group.

Exposure to the test article produced iritis in 2/6 test eyes at the 1 hour scoring interval which resolved completely in the affected eyes by the 24 hour scoring interval. Conjunctivitis (redness, swelling and discharge) was noted in 6/6 test eyes at the 1 hour scoring interval. The conjunctival irritation resolved completely in all animals by study day 7. No corneal opacity, iritis or conjunctivitis was observed in the control eyes.

Slightly irritating, Draize index 2 (110 = Maximum possible score)

Source : Arkema Inc. Philadelphia, PA USA

**Test condition** : Each of six rabbits received a 0.1 mL dose of the test

article in the conjunctival sac of the right eye. The test article was heated in a 37°C water bath and maintained at

room temperature. The test article was heated to liquefy but was not

diluted. The contralateral eye of each animal remained untreated and served as a control.

Prior to dosing, eyes of each animal were examined for ocular irritation with the aid of an auxiliary light source and the corneal surface was examined using fluorescein

sodium dye. Animals exhibiting ocular irritation,

preexisting comeal injury or fluorescein dye retention were not used on study.

Concentration Amount No. of Animals
Group Instilled Males Females
No Rinse 100% 0.1 mL 1 5

The eyes were macroscopically examined with the aid of an auxiliary light source for signs of irritation at 1, 24, 48 and 72 hours and up to 7 days after dosing according to the Ocular Grading System based on Draize. Following macroscopic observations at the 24 hour scoring interval, the fluorescein examination procedure was repeated on all test and control eyes and any residual test article was gently rinsed from the eye at this time (if possible) using physiological saline. If any fluorescein findings were noted at 24 hours, a fluorescein exam was conducted on the

response was obtained.

Test substance : Vikolox (R) 16

**Conclusion** : Under the conditions of this test, this substance is

considered to be an irritant to the ocular tissue of the

affected eyes at each subsequent interval until a negative

rabbit.

**Reliability** : (1) valid without restriction

22.12.2005 (20)

Species : rabbit

Concentration :

Exposure time : Comment :

Number of animals

Vehicle

**Result** : slightly irritating

Classification

Method : Draize Test

Year :

Test substance

Result : minor transient conjunctival irritation (Draize score - 2.0

at 24 hours)

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005

Species Concentration

Dose

Exposure time : Comment :

Number of animals Vehicle

Result : not irritating
Classification : not irritating

Method : Year :

GLP :

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (13)

**Id** 7320-37-8 5. Toxicity Date 23.12.2005

#### 5.3 SENSITIZATION

Type **Buehler Test** guinea pig Species

Concentration Induction 50 % occlusive epicutaneous

Induction 50 % occlusive epicutaneous Induction 50 % occlusive epicutaneous

**Number of animals** 20

Vehicle other: mineral oil Result sensitizing

Classification Method Year

**GLP** yes **Test substance** other TS

Method This study was performed to assess the dermal sensitization

potential (delayed contact hypersensitivity) in

Hartley-derived albino guinea pigs when administered by multiple topical applications. May 14, 1996 (GLP initiation

date).

Result A. Topical Range-Finding Studies: A test article

concentration of 50% w/v in mineral oil was the maximum

concentration that produced irritation. A concentration of 5% w/v in mineral

oil was the highest non-irritating

concentration and was therefore considered appropriate for

challenge.

B. Sensitization Study: Following Induction I @ 50% w/v in mineral oil, dermal scores of 1 were noted in 8/20 test

animals at the 24 hour scoring interval and dermal scores of 1 to 2 (three with very slight edema) were noted in 13/20 test animals at the 48 hour scoring interval. At Induction II, which was performed on the same test site

concentration as Induction I, dermal scores of 2 to 3 (all with very slight to moderate edema and some with blanching

and/or eschar) were noted in all test animals at both the 24 and 48 hour

scoring intervals. This increase in dermal

scores from Induction I to II may be partially attributed to primary irritation since the animals were dosed on the same test site. Following Induction III at 50% w/v, dermal scores of 2 to 3 (all with very slight to slight edema, 12/20 with blanching and 1/20 with eschar) were again noted in all test animals at the 24 hour scoring interval. At the 48 hour scoring interval, dermal scores of 1 to 3 (17/20 with very slight to slight edema and 7/20 with blanching) were noted in all test animals. Since Induction III was dosed on a naive test site, the increase in dermal scores when compared

with Induction 1 is probably an indication of sensitization. Following challenge with 5% w/v in mineral oil, dermal scores of 1 to 2 (two with very slight edema) were noted in 11/20 test animals at the 24 hour scoring interval. At the 48 hour scoring interval, dermal scores of 1 were noted in 3/20 test animals. Dermal reactions in the remaining test and all challenge control animals were limited to scores of 0 to t. Group mean dermal scores were noted to be slightly higher in the test animals as compared with the challenge

control animals.

Following rechallenge with 5% w/v in mineral oil, dermal scores of 1 to 2 (two with very slight edema) were noted in 10/20 test animals at the 24 hour scoring interval. At the 48 hour scoring interval, dermal scores of 1 to 2 (one with very slight edema) were noted in 6/20 test animals. Dermal reactions in the remaining test and all challenge control

animals were limited to scores of 0 to +. Group mean dermal scores were noted to be slightly higher in the test animals as compared with the challenge control animals.

Following rechallenge with 15% w/v in mineral oil, dermal

scores of 1 to 2 (most with very slight edema) were noted in 20/20 test animals at the 24 hour scoring interval and in 19/20 test animals at the 48 hour scoring interval. Dermal reactions in the remaining test and all challenge control animals were limited to scores of 0 to +/-. Group mean dermal scores were noted to be higher in the test animals as compared

with the challenge control animals.

Following rechallenge with 100% mineral oil, dermal scores of 0 to +/- were noted in all test and challenge control animals. Group mean dermal scores were noted to be similar in the test animals as compared with the challenge control

animals.

Source : Arkema Inc. Philadelphia, PA USA

**Test condition**: The test article was heated in a 37°C water bath (until

liquefied).

Young adult, Hartley-derived albino guinea pigs were used. Prior to dose administration, guinea pigs were weighed and

the hair removed from the right and left side of the animals with a small

animal clipper.

Induction was accomplished with a 50% solution applied to 10 male and 10

female guinea pigs on days 1, 7

and 13.

On the day prior to challenge dose administration, the test and challenge control animals were weighed and the hair was removed from the right side of the animals. On the day

following clipping (day 27), a 5% solution was administered for 6 hours.

A rechallenge was conducted in order to substantiate and

clarify the challenge results. On the day prior to rechallenge dose administration, all test and challenge control animals were weighed and the hair was then removed from the right side and left side of the animals. On the day following clipping (day 34), challenge doses of 5% and 15% were applied on

separate sites for 6 hours.

Test substance : Vikolox (R) 16

**Conclusion** : Based on the results of this study, this material is

considered to be a contact sensitizer in guinea pigs. The results of the hexylcinnamaldehyde historical control study demonstrated that the test design utilized would detect

potential contact sensitizers.

**Reliability** : (1) valid without restriction

22.12.2005

#### 5.4 REPEATED DOSE TOXICITY

Type : Species : rat

Sex: male/femaleStrain: Fischer 344Route of admin.: dermalExposure period: 13 weeksFrequency of treatm.: daily; 5/week

Post exposure period

**Doses** : 0, 62.5 mg/kg, 125, 250, 500, 1000; conc : 0, 3.75, 7.5, 15. 30, 60%

Control group : yes, concurrent vehicle LOAEL : = 125 mg/kg bw

Method : Method/guideline followed 90 day study

Test type Dermal skin painting GLP (Y/N) study was audited by NTP

Year (study performed) 1979
Species rat
Strain F344
Route of administration dermal

Doses/concentration levels 0, 62.5,125, 250, 500,

1000

conc: 0, 3.75, 7.5, 15. 30, 60%

Sex M&F

Exposure period 90 days
Frequency of treatment 5 days/week
Control group and treatment Vehicle control
Post exposure observation period 5 days
Statistical methods none
Age at study initiation 7 weeks

No. of animals per sex per dose 10; group housed

5/sex/cage

Vehicle Acetone

Dose volume adjusted on weight basis

Dose concnetration 4% - 60%

Clinical Observations Body weights weekly; 2x

daily checks for signs and mortality, detailed

observations 1/wk

Necropsy Gross pathology; organs examined: skin,

lymph nodes (mandibular, mesenteric)

mammary gland, salivary gland, thigh muscles, sciatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid, esophagus, stomach, duodenum, jejunum, ileum, colon, rectum, liver, pancreas, spleen, kidneys, adrenals, bladder, seminal vescicles, prostate, testes, ovaries, uterus, nasal cavity, brain, pituitary, eyes, external and

middle ear, spinal cord.

The data presented here were extracted from the records

maintained at the NTP archives.
Pathology QUALITY ASSESSMENT

REPORT OF THE SUBCHRONIC STUDY OF EPOXY HEXADECANE

(C55538)

IN Fischer 344 Rats and B6C3F1 Mice

#### **RATS**

There were lesions observed in this study. These skin lesions (site of application) were manifested in a variety of changes, changes consisted of hyperkeratosis, parakeratosis, acanthosis, necrosis of cells, and necrosis with varying degrees of inflammation. In more severe cases, mostly high dose and mid dose animals, there was ulceration of the skin accompanied with acute and chronic inflammation. In one case, high dose male, there were pyogenic granulomas deep in the dermis and muscle.

Lung lesions seen in this study are suggestive of being Sendi virus induced.

The reviewing pathologist concluded that there were no discrepancies noted which should alter the doses recommended for the chronic study.

Body weights: consistently slightly to moderately reduced @ 500 & 1000 for males; at termination ~20 and 35% lower than controls, and from the second week of dosing @ 250, 500, and 1000 slightly to moderately reduced for females; at termination 9, 27, 4, and 70% lower than controls

Result

Remark

**Id** 7320-37-8 5. Toxicity Date 23.12.2005

> Clinical signs: 62.5 mg/kg: (2 of 10 males) dark brown spots on treated areas weeks 3 - 8; weeks 9 - 13 hyperemic treatment area

250 mg/kg: weeks 3 - 9: all males exfoliation of stratum corneum; weeks 10 - 13 - sores on backs

500 mg/kg: weeks 3 - 8 - all animals exfoliation of stratum corneum and alopecia; in addition during weeks 9 -13 erythema and rough coats in some animals; some females thin

1000 mg/kg: weeks 1 - 3 rough coats and slight erythema; weeks 4 - 13 in addition exfoliation of the stratum corneum, week 5 - 13 dark urine, emaciation primarily in females, alopecia, sores in treated area.

Microscopic findings are limited to the skin and site of application. Deep dermal abscesses, focal ulceration, inflammation were reported.

Murine virus Antibody Determinations: PVM titers ranged from 80 - 40 in10/10 animals, KRV titers of 160 to 640 in 4/0 animals and Sendi titers of 80 - 320 in 10/10 animals.

Test substance

Mortality: none prior to study termination Arkema Inc. Philadelphia, PA USA

1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

Chemical Specification from Viking Chemicals Technical Bulletin for material used in NTP bioassay and supporting studies: Acid Value (mg KOH/g) 0.20 max

Oxirane Oxygen (theory - 6.66%) 6.12% min Peroxide number meg O/ 1,000 g 10 max Described as colorless cloudy liquid

Conclusion

: LOAEL = 125 mg/kg. The most suitable level for a chronic study would be 125 mg/kg.

: (2) valid with restrictions

During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute.

A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a category considered data not fully reliable. The explanation is: None of the flaws in any study in this category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.

### Source

Reliability

**Id** 7320-37-8 5. Toxicity Date 23.12.2005

> In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be

considered still less certain.

Critical study for SIDS endpoint Flag

22.12.2005 (12)

**Type** Species rat

Sex male/female Strain Fischer 344 Route of admin. dermal Exposure period 14 days Frequency of treatm. daily

Post exposure period

**Doses** O, 2.5%, 5%, 10%, 20%, 40% applied 0.6 ml

**Control group** yes, concurrent vehicle

**LOAEL** = 2.5 %

Method

Year

**GLP** no data **Test substance** other TS

Method Control group and treatment Vehicle acetone

> Post exposure observation period 5 days Statistical methods None Age at study initiation 8 weeks No. of animals per sex per dose

Vehicle Acetone Clinical Observations Body weights weekly

Necropsy Gross pathology

Remark The data presented here were extracted from the records

maintained at the NTP archives.

Result Clinical signs: Rough coats, tissue necrosis of treated

areas, dark urine; dose related body weight depression at

all levels

Gross necropsy findings: desquamation, alopecia, focal

irritation of the skin

Mortality: 1 female @ 20% and 2 females at 40%

Source Arkema Inc. Philadelphia, PA USA

: 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear **Test substance** 

> viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

Conclusion Body weight data indicate a dose related effect with all

test groups gaining less weight than controls and the 40% group losing more than 10 grams of body weight. At the 5% level and above, both sexes gained 19 to 150% less than controls. At the 2.5% level the males gained -14% and the females -6% relative to controls. Pathological changes consisted mostly of deaguamation and depilation at 10% and

above.

Reliability (4) not assignable

22.12.2005 (11)

**Type** 

Species mouse Sex male/female

Strain: B6C3F1Route of admin.: dermalExposure period: 13 weeksFrequency of treatm.: 5 days/week

Post exposure period

**Doses** : 0, 62.5, 125, 250, 500, 1000 mg/kg

Control group : yes, concurrent vehicle LOAEL : = 125 mg/kg bw

Method Year

GLP

Test substance : other TS

Method : Test type Dermal skin painting

GLP (Y/N) no

Year (study performed) 1979

Species Mouse

Strain B6C3F1

Route of administration Dermal; applied to shaved skin of

back ~ 1 sq inch area Duration of test13 weeks

Doses/concentration levels 0, 62.5 mg/kg, 125, 250, 500,

1000; conc: 0, 0.94%, 1.875, 3.75, 7.5, 15%

Sex M&F

Exposure period 90 days

Frequency of treatment 5 days/week
Control group and treatment Vehicle control
Post exposure observation period 5 days

Statistical methods None

Age at study initiation 7 weeks

No. of animals per sex per dose 10; group housed 5/sex/cage

Vehicle Acetone

Clinical Observations Body weights weekly; 2x daily checks

for signs and mortality, detailed observations 1/wk;

Necropsy

Gross pathology; organs examined: skin, lymph nodes (mandibular, mesenteric) mammary gland, salivary gland, thigh muscles, sciatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid,

esophagus, stomach, duodenum, jejunum, ileum, colon, rectum,

liver, pancreas, spleen, gall bladder, kidneys, adrenals, bladder, seminal vescicles, prostate, testes, ovaries, uterus, nasal cavity, brain, pituitary, eyes, external and

middle ear, spinal cord.

Remark : Pathology QUALITY ASSESSMENT

REPORT OF THE SUBCHRONIC STUDY OF EPOXY HEXADECANE

(C55538)

IN Fischer 344 Rats and B6C3F1 Mice

MICE

Dose related lesions were encountered in the skin (target organ). The reviewing pathologist concluded that there were no

discrepancies noted which should alter the

recommendations for the chronic study. The lung lesions seen in this study are suggestive of being Sendi virus

induced.

**Result** : Body weights: reduced body weights in males at > 250;

beginning in the fourth week the mean body weights of the 1000 and 250 were slightly to moderately and 500 very slightly to slightly less than the controls. Mean body

weights @ 500 dipped markedly during week 6 but recovered to near control values in week 7; mean body weights recovered

**Id** 7320-37-8 5. Toxicity Date 23.12.2005

> to near controls for all doses by end of the study; mean body weights of females varied too widely for any meaningful relationship to treatment.

Clinical signs: cutaneous reactions: exfoliation of the corneum layer of the skin, alopecia, hyperemia, and or blanching at application site @ > 250 in males and @ 1000 in females

Clincial observations: males:Control - sores on back likely due to fighting

250 mg/kg: sores on back likely due to fighting; Weeks 3 -6 treatment area looks pale; week 7 some with thin appearance, Week 8 -- 2 found dead

500 mg/kg: weeks 3 - 6 - all animals exfoliation of stratum corneum and blanching of the skin; week 7 -- 4 found dead, survivors appear thin; weeks 7 -13: conditions of survivors improves

1000 mg/kg: weeks 1 - 2 exfoliation of the stratum corneum and alopecia of treated area; week 3 -- one found dead; week 7 -- 6 found dead; week 11 3 animals with sores on dorsal area; week 12 -- one found dead.

Clinical observations, females:250 mg/kg: weeks 3 - dark patches or blanching on treated area (1 each) Week 7 -- 3 found dead; Weeks 8-9 rough coats, thin; Weeks 8 - 13: conditions improve

500 mg/kg: Week 7: 3 found dead, others thin; Week 8: 1 found dead; Weeks 9 - 13 condition improves 1000 mg/kg: Week 1 slight erythema of treated area; week 2: exfoliation of the stratum corneum of treated area; weeks 3 - 6: exfoliation of the stratum corneum and alopecia of treated area; Week 6 one found dead; Week 7 -- 3 found dead; Weeks 7 - 13: thin appearance and continued dermal effects.

Microscopic findings -- hyperkeratosis (minimal to moderate) in 14 mice, parakeratosis in 3 mice, and epithelial hyperplasia in 8 mice. Except for the tissue changes in the skin of treated mice there were no tissue changes attributable to the effects of the test material in any of the treated mice examined. Mortality: 2m/3f @ 250; 4m/4f @ 500; 8m/4f @ 1000 mg/kg; most deaths occurred during weeks 6 - 8

Source Test substance Arkema Inc. Philadelphia, PA USA

: 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months: Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

Conclusion Reliability

LOAEL - 125 mg/kg. Treatment related dermal lesions

(2) valid with restrictions

During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute. A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a

category considered data not fully reliable. The explanation is: None of the flaws in any study in this category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.

In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be considered still less certain.

22.12.2005 (11)

Type

Species: mouseSex: male/femaleStrain: B6C3F1Route of admin.: dermalExposure period: 14 daysFrequency of treatm.: dailyPost exposure period: 5 days

**Doses** : 0, 2.5%, 5%, 10%, 20%, 40% applied 0.2 ml

Control group : yes, concurrent vehicle

NOAEL : = 5 % LOAEL : = 10 %

Method Year GLP

Remark

Test substance : other TS

Method : Method/quideline Range finding study for 90 day study

Test type 14 day dermal
Year (study performed) 1979
Species mouse
Strain B6C3F1
Route of administration
Frequency of treatment daily

Vehicle acetone

Post exposure observation period 5 days
Statistical methods none
Age at study initiation 8 weeks

No. of animals per sex per dose
Clinical Observations

5
Body weights weekly

Necropsy Gross pathology
: The data presented here were extracted from the records

maintained at the NTP archives.

Result : Body weights (grams)

Males Females Start End Start End Control 28.0 28.4 20.4 22.0 2.5% 28.0 28.6 20.4 21.8 5% 27.6 30.2 19.4 22.6 10% 28.4 27.2 20.0 22.0 20% 28.8 26.4 19.4 18.6 40% 27.6 23.0 20.8 18.2

Gross necropsy records showed alopecia and small skin ulcers

with the alopecia varying from focal area at the application site to 90% of the body. This alopecia was assumed to be compound related since large patches of hair were observed falling out during the test and this was not seen in controls. Clinical signs included tissue necrosis loss of equilibrium and difficulty walking. Mortality: all high dose females and I high dose male died during the 5 day

post dosing observation period. No other mortalities.

Source : Arkema Inc. Philadelphia, PA USA

**Test substance** : 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear

viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

**Conclusion** : Body weight data indicate a probable toxic effect at 10% and

above in males and 20% and above in females.

**Reliability** : (4) not assignable

22.12.2005 (11)

### 5.5 GENETIC TOXICITY 'IN VITRO'

**Type** : Salmonella typhimurium reverse mutation assay

System of testing : Test concentration : Cycotoxic concentr. :

Metabolic activation

Test substance

Source

Result : negative

Method : Year :

GLP :

Reliability : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

22.12.2005 (1)

Arkema Inc. Philadelphia, PA USA

**Type** : Salmonella typhimurium reverse mutation assay

System of testing
Test concentration
Cycotoxic concentr.

Metabolic activation

**Result** : negative

Method Year

GLP :

Test substance

Source : Arkema Inc. Philadelphia, PA USA Flag : Critical study for SIDS endpoint

22.12.2005 (22)

**Type** : Sister chromatid exchange assay

System of testing : CHO cells

Test concentration : Cycotoxic concentr. : Metabolic activation :

Result : negative

00

Method :
Year :
GLP :
Test substance :

Source : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

22.12.2005 (15)

**Type** : Sister chromatid exchange assay

System of testing : Chinese Hamster Cells

Test concentration
Cycotoxic concentr.
Metabolic activation

Metabolic activation :

Result : negative

Method Year

Year : GLP :

Test substance

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (23)

Type : Ames test

**System of testing** : TA98, TA100, TA1535, TA1537, TA1538

Test concentration : Cycotoxic concentr. :

Metabolic activation

Result : negative

Method Year

GLP Test substance

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (5)

**Type**: Mouse lymphoma assay

System of testing
Test concentration
Cycotoxic concentr

Cycotoxic concentr.
Metabolic activation

Result : positive

Method : Year :

GLP :

Test substance :

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (6)

**Type** : Salmonella typhimurium reverse mutation assay

System of testing : Test concentration : Cycotoxic concentr. :

Metabolic activation

Result : negative

Method :

Year : GLP :

Test substance

Source : Arkema Inc. Philadelphia, PA USA

22.12.2005 (9)

#### 5.6 GENETIC TOXICITY 'IN VIVO'

#### 5.7 CARCINOGENICITY

Species : rat

Sex : male/female
Strain : Fischer 344
Route of admin. : dermal
Exposure period : 2 years

Frequency of treatm. : 5 days/week for 103 weeks

Post exposure period : 1 week

**Doses** : 125, 62.5 mg/kg

Result

Control group : yes, concurrent vehicle

Method :
Year :
GLP :
Test substance :

Method : Method/guideline followed chronic bioassay

Test type Dermal skin painting GLP (Y/N) study was audited by NTP

Year (study performed) 1980
Species rat
Strain F344
Route of administration dermal
Doses/concentration levels 0, 62.5,125
conc: 0, 3.75, 7.5 (adjusted

based on body weight to allow for administration of 600

microliters)

Sex M&F

Exposure period 103 weeks
Frequency of treatment 5 days/week
Control group and treatment Vehicle control
Post exposure observation period 5 days
Statistical methods Fischers exact test
no. of animals per sex per dose 50; group housed

5/sex/cage

Vehicle Acetone

Clinical Observations Body weights weekly for first thirteen weks then monthly; 2x daily checks for signs and mortality, detailed observations 1/wk and palpated for

masses

Interim sacrifices None Special studies None

Moribund animals need for unscheduled sacrifice and necropsy determined by veterinarian or

toxicologist; tissues preserved

Necropsy

Gross pathology: gross lesions and tissue masses and

regional lymph nodes

organs examined: adrenals, bladder, blood smear brain (3 sections),

colon,

duodenum,

ear, external and middle

esophagus, eyes, heart, ilem, jejunum, kidneys, larynx,

liver,

lungs and bronchi,

lymph nodes (mandibular, mesenteric)

mammary gland, nasal cavity, ovaries, pancreas, parathyroid,

pituitary, prostate,

rectum,

salivary gland, sciatic nerve,

seminal vesicles,

skin,

small intestine (one section)

spinal cord. spleen,

sternebrae, femur or vertebrae including bone marrow,

stomach, testes, thigh muscle, thymus, thyroid,

trachea,

uterus,

: The data presented here were extracted from the records

maintained at the NTP archives.

: No compound related toxicological effects were observed during most of the chronic study. No striking toxicological effects were observed when observation data for each treatment group was compared to controls.

Some non significant differences were seen between the groups for non-tumour pathology. Changes noted in the skin were significant and are listed below by sex and dose group

Males **Females** % C low high c low high Inflammation focal 2 2 chronic 2 6 8 chronic & focal 2 acute 2 32 / 43

Remark

Result

acute & focal 2 acute & chronic 2 Hyperplasia NOS 32 26 26 epithelial 2 focal 2 2 2 Hyperkeratosis 12 18 12 Sclerosis dermis 2

It is apparent that the test material is a skin irritant and induces proliferative changes when applied topically.

No consistent compound related reduction in body weight occurred in any of the treatment groups. Periodic weight fluctuations were attributed to problems with the automatic watering system.

Results of Post Pathology Working Group (PWG)
PATHOLOGY NARRATIVE OF 1,2-EPOXYHEXADECANE (C55538) IN
B6C3FI MICE AND FISCHER 344 RATS August 11, 1983

#### **Neoplastic Lesions**

There was reported an increased incidence of adenomas of the anterior pituitary gland in female rats. These neoplasms are well circumscribed usually solid masses of a single cell type that are moderately well demarcated from, and compress, surrounding tissue. Areas of trabecular formation are sometimes found and cavernous, blood-filled vessels often give the impression of hemorrhage in early lesions. In older, larger tumors the pools of blood may be lined with tumor cells rather than endothelium.

The PWG found additional tumors in all groups of female rats. in addition, there was unequal sampling among the groups with the greatest number of tissue specimens available in the test groups.

Pituitary - Adenomas - Female Rats

Control Low Dose High Dose Original 13/50 (26%) 21/47 (45%) 18/48 (38%)

PWG 19/79 (24%) 25/104 (24%) 24/90 (26%)

Source Conclusion

Reliability

: Arkema Inc. Philadelphia, PA USA

RATS Pathology Working Group CONCLUSIONS

1,2-Epoxyhexadecane in a two-year skin paint study did not produce any compound related neoplastic or systemic toxic lesions in F344 rats.

: (2) valid with restrictions

During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute.

A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report

on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a category considered data not fully reliable. The explanation is: None of the flaws in any study in this

category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.

In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be considered still less certain.

22.12.2005 (11)

Species: mouseSex: male/femaleStrain: B6C3F1Route of admin.: dermalExposure period: 2 years

Frequency of treatm. : 5 days/week for 103 weeks

Post exposure period : 1 week

**Doses** : 125, 62.5 mg/kg

Result

**Control group** : yes, concurrent vehicle

Method

Year : 1980

GLP :

Test substance :

Method : Test type Dermal skin painting

GLP (Y/N) Study audited by NTP

Year (study performed) 1980
Species Mouse
Strain B6C3F1

Route of administration Dermal; applied to shaved skin of

back ~ 1 sq inch area Duration of test103 weeks

Dose levels 0, 62.5, 125 mg/kg concnetrations adjusted

based on body weight to allow administration of 200

microliters.

Sex M & F

Exposure period 103 weeks

Frequency of treatment 5 days/week
Control group and treatment
Post exposure observation period 5 days

Statistical methods None

No. of animals per sex per dose 50; group housed 5/sex/cage

Vehicle Acetone

Clinical Observations Body weights weekly for first 13 weeks

then monthly; 2x daily checks for signs and mortality, detailed observations 1/wk and palpated for massed

Interim sacrifices None Special studied None

Moribund animals need for unscheduled sacrifice and necropsy determined by veterinarian or

toxicologist; tissues preserved

Necropsy

Gross pathology; organs examined: skin, lymph nodes (mandibular, mesenteric) mammary gland, salivary gland, thigh muscles, sciatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid, esophagus, stomach, duodenum, jejunum, ileum, colon, rectum, liver, pancreas, spleen, gall bladder, kidneys, adrenals, bladder, seminal vescicles, prostate, testes, ovaries, uterus, nasal cavity, brain, pituitary, eyes, external and middle ear, spinal cord.

Remark

The data presented here were extracted from the records

maintained at the NTP archives.

Result : Pathology Working Group

PATHOLOGY NARRATIVE OF 1,2-EPOXYHEXADECANE (C55538) IN B6C3FI MICE AND FISCHER 344 RATS August 11, 1983

1. All groups of male mice, including controls, had a high incidence of subcutaneous, mesenchymal neoplasms as follows:

Subcutaneous Neoplasms - Male Mice Control Low Dose **High Dose** Malignant Sarcoma NOS 1 3 4 5 Fibrosarcoma 2 4 Neurofibrosarcoma 1 Combined 4 (8%) 7 (14%) 9 (18%) Benign Fibroma 1 1 **Total Combined** Incidence 5 (10X) 8 (16%) 13 (26%)

The distribution of the lesions on the body were back 19, abdomen 3, side 2 and leg and axilla one each. Only one fibrosarcoma was clearly identified as occurring at the application site. The tumors were all visible grossly and varied in size up to  $6.0 \times 3.5 \times 2.4$  cm.

Microscopically fibromas are composed of fusiform or stellate cells with pale, ovoid or rounded nuclei. The cells produce interlacing bundles of collagen fibers which may be densely packed or loosely arranged as if separated by edema or a mucinous ground substance. The tumors are relatively well circumscribed and non-invasive. Fibrosarcomas are more cellular and produce less collagen. They are locally invasive and may metastasize. Neurofibrosarcomas are similar to fibrosarcomas. They are characterized by bundles of cells and fibers that are arranged in whorls which when cut longitudinally produce a herring :one pattern. They are believed to arise from nerve sheaths. Many pathologists do not differentiate them from fibrosarcomas. Sarcoma NOS are extremely cellular tumors which may contain large bizarre nuclei, mitotic figures and multinucleated giant cells. A pattern of interwoven bundles of fusiform cells may be apparent but collagen fibers are difficult to demonstrate in any quantity even with polarized light. They may be locally invasive and metastasize.

2. There was a modest increase in the incidence of hepatocellular adenomas in all groups of male mice as follows:

Hepatocellular Neoplasms - Male Mice

Control Low Dose High Dose Adenoma 13 (27%) 14 (29%) 11 (22%) Carcinoma 4 (8%) 10 (21%) 9 (18%)

Combined

Incidence 17 (34%) 24 (48%) 20 (40%)

The incidence of hepatocellular carcinoma was low in control male mice and average for treated animals.

Hepatocellular adenomas microscopically have well defined borders that may be scalloped and which compress the surrounding parenchyma. There are variations in cell morphology and absence of triads. Organization is of a solid or trabecular type or a combination of both. Solid areas are composed of closely packed cells resembling normal hepatocytes in which sinusoids are rarely seen. The trabecular type has a clear cut cord structure with sinusoids separating the cords. Cords may radiate from blood vessels giving a pseudo-lobular appearance. In some tumors fatty change or vacuolation of the cytoplasm is prominent.

Hepatocellular carcinomas also occur in solid, trabecular and mixed patterns. Cells comprising the solid pattern vary greatly in cell and nuclear size and giant cells with large hyperchromatic nuclei are frequently present. The trabecular pattern differs from that of the adenoma in that the cords are many cells thick. Dilation of the sinusoids produces disruption of the regular trabecular pattern and necrosis and hemorrhage is common.

Source Test substance Arkema Inc. Philadelphia, PA USA

1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

Conclusion

The pathology working group concluded that 1,2-epoxyhexadecane in a two year skin painting study was associated with a dose-related increase in subcutaneous mesenchymal neoplasms in male B6C3F1 mice. A clear relationship between the location of the neoplasms and the area of skin exposure to the test compound cannnot be established from the data except for one tumor.

There were no other neoplastic or systemic toxic compound related effects in B6C3F1 mice. The pathology working group considered the modest increase in hepatocellular tumors in male mice not to be of biological significance.

Reliability

(2) valid with restrictions

During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute. A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a category considered data not fully reliable. The

explanation is: None of the flaws in any study in this category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.

In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be considered still less certain.

22.12.2005 (11)

- 5.8.1 TOXICITY TO FERTILITY
- 5.8.2 DEVELOPMENTAL TOXICITY/TERATOGENICITY
- 5.8.3 TOXICITY TO REPRODUCTION, OTHER STUDIES
- 5.9 SPECIFIC INVESTIGATIONS
- 5.10 EXPOSURE EXPERIENCE
- 5.11 ADDITIONAL REMARKS

6. Analyt. Meth. for Detection and Iden	tification Id Date	7320-37-8 23.12.2005
6.1 ANALYTICAL METHODS		
6.2 DETECTION AND IDENTIFICATION		
38 / 43	3	

7. Ef	f. Against Target Org. and Intended Uses	7320-37-8 23.12.2005	
7.1	FUNCTION		
7.2	EFFECTS ON ORGANISMS TO BE CONTROLLED		
7.3	ORGANISMS TO BE PROTECTED		
7.4	USER		
7.5	RESISTANCE		

# **Id** 7320-37-8 8. Meas. Nec. to Prot. Man, Animals, Environment Date 23.12.2005 8.1 METHODS HANDLING AND STORING 8.2 FIRE GUIDANCE 8.3 EMERGENCY MEASURES 8.4 POSSIB. OF RENDERING SUBST. HARMLESS 8.5 **WASTE MANAGEMENT** SIDE-EFFECTS DETECTION 8.7 SUBSTANCE REGISTERED AS DANGEROUS FOR GROUND WATER 8.8 REACTIVITY TOWARDS CONTAINER MATERIAL

## 9. References Id 7320-37-8 Date 23.12.2005

(1)	Canter DA, et al. Comparative Mutagenicity of Aliphatic Epoxides in Salmonella. Mutat Res 172(2):105-138, 1986. Negative.
(2)	Deneer JW, Sinnige TL, Seinen W and Hermens JLM, A Quantitative Structure Activity Relationship for the Acute Toxicity of Some Epoxy Compounds to the Guppy, Aquatic Toxicology 13: 195-204, 1988.
(3)	Dow Europe GMBH MSDS alpha-Olefin Epoxide C-16, 30/3/04
(4)	EPI Suite v3.12, modeling program, US EPA
(5)	Hengler, W.C., Slesinski, R.S. and Frank, F.R. (1984). a-olefin epoxide C-16 Salmonella/Microsome (Ames) bacterial mutagenicity assay.
(6)	McGregor DB, et al. Responses of the L5178Y TK+/TK- Mouse Lymphoma Cell Forward Mutation Assay: III. 72 Coded Chemicals. Environ Mol Mutagen 12(1):85-154, 1988.
(7)	MPBPWIN v1.41 modeling program in EPI Suite v 3.12, US EPA
(8)	Myers, R.C. and Christopher, S.M. (1992) cutaneous and ocular irritancy testing using the rabbit.
(9)	National Institute of Health. Comparative Mutagenicity of Aliphatic Epoxides in Salmonella. TSCA Section 4 submission. TSCATS Microfiche No. 522513
(10)	NIST/EPA Gas Phase Infrared Database. Internet Website: webbook.nist.gov
(11)	NTP Unpublished study (C55538)
(12)	NTP Unpublished study, Fiche C55538 GS SUBCHRONIC TEST 13
(13)	Nycum, J.S. (1968). Single dose toxicity and irritation studies on Epoxides
(14)	Safety and Toxicity Data prepared for 1,2-epoxyhexadecane by Tracor Jitco July 26, 1978.
(15)	Slesinski, R.S. and Frank, F.R. (1984). a-Olefin Epoxide C-16 in vitro Genotoxicity Studies: Sister Chromatid Exchange Test.
(16)	SPRINGBORN ENVIRONMENTAL SCIENCES Acute Oral Toxicity Study in Rats with Vikolox 16, SLI STUDY NO. 3255.80, 19 August 1996.
(17)	SPRINGBORN ENVIRONMENTAL SCIENCES Dermal Sensitization Study in Guinea Pigs with VIkolox 16, SLI STUDY NO. 3255.84, 10 Sept 1996.
(18)	SPRINGBORN ENVIRONMENTAL SCIENCES, Primary SKin Irritation Study in Rabbits with VIkolox 16, SLI STUDY NO. 3255.83 19 August 1996.
(19)	SPRINGBORN ENVIRONMENTAL SCIENCES. Acute dermal toxicity study in rats with Vikolox 16, SLI STUDY NO. 3255.81, 19 August 1996.

### **Id** 7320-37-8 9. References Date 23.12.2005 SPRINGBORN ENVIRONMENTAL SCIENCES. Primary Eye Irritation Study in Rabbits (20)with Vikolox 16, SLI STUDY NO. 3255.82, 19 August 1996. (21)The Dictionary of Substances and Their Effects (DOSE, 3rd Electronic Edition) 2005 by The Royal Society of Chemistry/Knovel Corp. (22)Union Carbide Corporation. Alpha-Olefin Epoxide C-16 Salmonella/Microsome (Ames) Bacterial Mutagenicity Assay With Cover Letter. TSCA 8(d) submission. TSCATS Microfiche No. 206602. 03/05/84. von der Hude W, Carstensen S and Obe G. Structure-Activity (23)Relationships of Epoxides: Induction of Sister- Chromatid Exchanges in Chinese Hamster V79 Cells. Mutat Res 249(1):55-70, 1991. (24)Waggy, G.T. (1992). Ecological fate and effects data on alpha-olefin epoxide C16. Watabe, T and Yamada N. The biotransformation of (25)1-hexadecene to carcinogenic 1,2-epoxyhexadecane by hepatic microsomes. Biochemical Pharmacology 24: 1051-1053, 1975. Wood WP, Properties Of Alkyl-Epoxides - Table I With Cover Letter, US Environmental (26)Protection Agency EPA/OTS DOC 40-8277016, NTIS/OTS0508875, 1982

10. Summary and Evaluation	7320-37-8 23.12.2005	
10.1 END POINT SUMMARY		
TO.1 END FORT COMMANT		
10.2 HAZARD SUMMARY		
10.3 RISK ASSESSMENT		